Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

Stellar2X Jun. 18 at 9:57 PM

$JNJ $RIOT $NOC $CLSK tam

0 · Reply

Orchard Jun. 18 at 7:53 PM

$MRNA Jesus the levels of trust in pharma is off the charts here. It is and never was a vaccine. Screenshot this morons. They had to LEGALLY change the definition so the public would take it because it is a GENE therapy. $JNJ can’t even make baby powder w/o asbestos or sunscreen w/o cancer causing chemicals and you trust their “studies” Trust an honest strip club operation $RICK more than anything pharma says.

1 · Reply

PittsburghTrader Jun. 18 at 7:12 PM

$JNJ thought might try to recover back > $230 into the close but guess not

0 · Reply

Orchard Jun. 18 at 6:24 PM

$MRNA The Covid Vaxx “gene therapy” has shown these companies will bury adverse effect data like $JNJ $PFE to seal the records for 55 yrs. Remember this companies poisoned people as they were NEVER 100% safe and effective. My friend literally went blind in his right eye from their unneeded “cure”. Trust the Strip Club $RICK before I’d ever let them inject me or my child with essentially was the largest medical experiment with the world as it’s Guinea pigs

2 · Reply

Bazziggr Jun. 18 at 4:54 PM

$JNJ & BSX

0 · Reply

PittsburghTrader Jun. 18 at 4:18 PM

$JNJ wow, just b/c $QQQ rallying gets this kind of pullback?

0 · Reply

Estimize Jun. 18 at 2:15 PM

Wall St is expecting 2.85 EPS for $JNJ Q2 [Reporting 07/15 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont

0 · Reply

Quantumup Jun. 18 at 10:24 AM

BofA🏁 $IMMX and said: We initiate coverage of IMMX with a Buy rating and $27 PO. $PRTA $JNJ - GMAB ABBV REGN AZN BofA added: IMMX is developing NXC201 for AL amyloidosis, a rare disease with damaged vital organs and no approved treatments. Early data of NXC-201 shows ~95% complete response and rapid minimal residual disease in relapsed/refractory (r/r) AL amyloidosis. The safety profile was favorable for patients facing potential organ failure with no observed neurotoxicity. Updated phase 2 data is expected in late September, and 1-year follow-up data is expected in 1Q27 to support a potential BLA submission in 1H27. If approved, we think a clinical profile with deep and rapid response and tolerability could be key for adoption.

0 · Reply

QHD Jun. 18 at 9:04 AM

$JNJ becomes a new front runner for acquiring Iovance. But they better get us before the lung data if they want us for less than $10 Billion. $IOVA From Google AI:

2 · Reply

yellowstar16 Jun. 18 at 3:49 AM

$JNJ https://www.foxnews.com/health/cure-certain-cancers-realistic-goal-next-decade-pharma-lead-says

0 · Reply

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

AMCR LOW

2026-06-15T11:17:46.000Z - 3 days ago

Johnson & Johnson (JNJ) Boosts Eye Care Business in $55B U.S. Manufacturing Push

2026-06-15T10:05:07.000Z - 3 days ago

Johnson & Johnson invests more than $1B in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 3 days ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 5 days ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 5 days ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

2026-06-11T11:50:10.000Z - 7 days ago

Johnson & Johnson expands U.S. availability of TECNIS PureSee IOL

Jun 11, 2026, 7:45 AM EDT - 7 days ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:14 AM EDT - 7 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

2026-06-11T09:26:54.000Z - 7 days ago

Johnson & Johnson presents first results from ENERGY study

Jun 11, 2026, 2:03 AM EDT - 7 days ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 8 days ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 8 days ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 9 days ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 9 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 10 days ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

2026-06-08T13:00:56.000Z - 10 days ago

M&A News: Johnson & Johnson (JNJ) Reaches a Massive $1B Deal for Firefly Bio to Expand Its Oncology Pipeline

2026-06-08T12:14:56.000Z - 10 days ago

Johnson & Johnson to acquire Firefly Bio for $1B in cash

Jun 8, 2026, 8:08 AM EDT - 10 days ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:00 AM EDT - 10 days ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 5, 2026, 6:24 PM EDT - 13 days ago

J&J beats lawsuit alleging that talc caused three women's cancer

2026-06-03T09:38:11.000Z - 15 days ago

Johnson & Johnson presents exploratory analyses from DAHLIAS study

2026-06-03T09:31:04.000Z - 15 days ago

Johnson & Johnson announces nipocalimab met primary endpoint in JASMINE study

Jun 3, 2026, 12:04 AM EDT - 15 days ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Jun 3, 2026, 12:03 AM EDT - 15 days ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 2, 2026, 6:24 PM EDT - 16 days ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

May 31, 2026, 8:39 AM EDT - 18 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:29 AM EDT - 18 days ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:27 AM EDT - 18 days ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:01 AM EDT - 18 days ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 29, 2026, 2:00 PM EDT - 20 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 8:18 AM EDT - 20 days ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 28, 2026, 7:10 PM EDT - 20 days ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 5:30 AM EDT - 21 days ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 27, 2026, 4:22 PM EDT - 22 days ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 11:00 AM EDT - 22 days ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 21, 2026, 7:00 AM EDT - 4 weeks ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 4:31 AM EDT - 4 weeks ago

Johnson & Johnson says nipocalimab approved in China

May 19, 2026, 11:30 AM EDT - 4 weeks ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 9:00 AM EDT - 4 weeks ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 14, 2026, 4:01 PM EDT - 5 weeks ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

May 12, 2026, 2:20 PM EDT - 5 weeks ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 7:45 AM EDT - 5 weeks ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 11, 2026, 4:34 PM EDT - 5 weeks ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 8:00 AM EDT - 5 weeks ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 7, 2026, 11:34 AM EDT - 6 weeks ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 8:00 AM EDT - 6 weeks ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 5, 2026, 9:15 AM EDT - 6 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS

May 5, 2026, 8:05 AM EDT - 6 weeks ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

$Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease$

May 5, 2026, 8:05 AM EDT - 6 weeks ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 7:00 AM EDT - 6 weeks ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 4, 2026, 8:00 AM EDT - 6 weeks ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 2, 2026, 4:00 AM EDT - 6 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Apr 30, 2026, 8:02 AM EDT - 7 weeks ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 28, 2026, 11:10 AM EDT - 7 weeks ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Apr 27, 2026, 4:33 PM EDT - 7 weeks ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 11:03 AM EDT - 7 weeks ago

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 8:03 AM EDT - 7 weeks ago

FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA)

Apr 24, 2026, 4:30 PM EDT - 7 weeks ago

Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports

Apr 23, 2026, 6:44 PM EDT - 2 months ago

Cramer says look to these 4 stocks to go with your high-flying tech names

CAH CVS UNH

Apr 23, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: AGM 2026

Apr 22, 2026, 8:05 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 4:00 AM EDT - 2 months ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 21, 2026, 4:22 PM EDT - 2 months ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Stellar2X Jun. 18 at 9:57 PM

$JNJ $RIOT $NOC $CLSK tam

0 · Reply

Orchard Jun. 18 at 7:53 PM

1 · Reply

PittsburghTrader Jun. 18 at 7:12 PM

$JNJ thought might try to recover back > $230 into the close but guess not

0 · Reply

Orchard Jun. 18 at 6:24 PM

2 · Reply

Bazziggr Jun. 18 at 4:54 PM

$JNJ & BSX

0 · Reply

PittsburghTrader Jun. 18 at 4:18 PM

$JNJ wow, just b/c $QQQ rallying gets this kind of pullback?

0 · Reply

Estimize Jun. 18 at 2:15 PM

Wall St is expecting 2.85 EPS for $JNJ Q2 [Reporting 07/15 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont

0 · Reply

Quantumup Jun. 18 at 10:24 AM

0 · Reply

QHD Jun. 18 at 9:04 AM

$JNJ becomes a new front runner for acquiring Iovance. But they better get us before the lung data if they want us for less than $10 Billion. $IOVA From Google AI:

2 · Reply

yellowstar16 Jun. 18 at 3:49 AM

$JNJ https://www.foxnews.com/health/cure-certain-cancers-realistic-goal-next-decade-pharma-lead-says

0 · Reply

JuggernautRaider Jun. 18 at 1:56 AM

$TNXP hell yea brother 👊 I found out my mom has breast cancer today . I will be looking after her. My mon taught me so much; God bless all our mothers, especially ahead of Juneteenth and Father’s day here in the US. 🇺🇸 Just block those FUDDing bears 🐻 I am a Tonixphile and a 🐂 I am a big believer in $IMRX , $CCCC , and Enhertu too. I recall the ASCO plenary session well - I was there for one the oncology companies I worked for. Maybe it was Be a Mess, Celgene, or another like $JNJ Anyway, I will be busy. @alphaonetrading , @Proposition_Joe, others: I will be in touch. 🤫 John 3:16 📕

7 · Reply

Sell_SoFi Jun. 17 at 11:38 PM

$JNJ Cure for certain cancers is ‘realistic’ goal in next decade, pharma lead says.. Johnson & Johnson CEO cites immunotherapy breakthroughs in multiple myeloma, remission rates and longevity https://www.foxnews.com/health/cure-certain-cancers-realistic-goal-next-decade-pharma-lead-says

0 · Reply

kiwitc2000 Jun. 17 at 7:06 PM

$JNJ Entering the support zone around 232. Curious to see if that holds before entering.

0 · Reply

Orchard Jun. 17 at 5:48 PM

$MRNA The company makes poison Vaxx that has destroyed people’s lives. Every day more and more formally suppressed data shows this “gene therapy” goes into ovaries. $JNJ couldn’t even make baby powder w/out asbestos and sunscreen without cancer chemicals $PFE with cholesterol scam drugs $LLY trying to own GLPs. Ozempic and Monjero are made from Gila Monster venom compounds. They tried to hide all the deaths and side effects and you morons keep trusting them.

0 · Reply

AStrokeOfLuck Jun. 17 at 5:02 PM

$JNJ $NVO $LLY $AMGN $VKTX

3 · Reply

Skimman Jun. 17 at 2:19 PM

$JNJ little OVERBLOWN here

0 · Reply

Suite510 Jun. 17 at 2:10 PM

$JNJ $KVUE $SPX June 16, 2026 😬💰 J&J Fails To Undo $65.5M Verdict In Minn. Talc Cancer Case A Minnesota state judge on Monday upheld a $65.5 million verdict awarded to a mother of three children who had claimed that Johnson & Johnson's talc products exposed her to asbestos and contributed to her cancer, saying that the jury's decision was supported by the evidence at trial.

1 · Reply

TraderDaKing Jun. 17 at 1:56 PM

$ELTP $PFE $JNJ $SPCX $GME Elite Pharmaceuticals’ Sequestox: Poised to Become the Gold Standard in Drug Space Pending FDA Approval. Elite Pharmaceuticals is generating significant buzz in the pharmaceutical industry with its promising new drug, Sequestox. This innovative treatment is currently pending FDA approval and is widely anticipated to set a new benchmark in its therapeutic category. Go ELTP !.... More News Coming.....

0 · Reply

Skimman Jun. 17 at 1:49 PM

$JNJ WTF....

1 · Reply

BarkingPuppy Jun. 17 at 1:43 PM

$PFE $JNJ New Buy-out and or merger.

0 · Reply

RetailWolfie Jun. 17 at 1:28 PM

$JNJ showed a beautiful wick touching the 50DMA as a retest Still holding this support area, looking to see another breakout attempt!

0 · Reply

cwEWF Jun. 17 at 9:34 AM

$JNJ favors rally in 5 of (1), while dips remain above 6.01.2026 low to extend rally It favors rally towards 259.3 or higher from daily #Bluebox area to extend bull run started from January-2025 low. Are you long from #bluebox area or still waiting? #Elliottwave #JNJ

0 · Reply

Market Cap	566.13B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	21.96
Forward PE	20.37
Profit Margin	28.46%
Debt to Equity Ratio	0.46

Volume	18,987,900
Avg Vol	7,766,966
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	41%
Beta	0.26
Analysts	Strong Sell
Price Target	$260.46